We are pleased to report that Priligy is now back in stock and will be in our pharmacy from 11 January. We will be able to dispense this item again for next day delivery. If you are already registered with us then you can login to your account to make a prescription request – please remember to check that your medical details are up to date! If you have not yet registered with us then you can do so by clicking on the free consultation button below.

Priligy, the treatment for premature ejaculation is out of stock at the moment because of a supply chain issue. We expect this problem to be resolved in the next few days. We can still take orders for new prescriptions and dispense them as soon as the stock comes in if you wish to be on the waiting list. Alternatively, please continue to check this news feed and we will update the page when the situation changes.

One of the scientists responsible for the invention of Viagra has done it once again and has created a revolutionary treatment for those who suffer from premature ejaculation (PE). The treatment, named Tempe, is simply sprayed on in order to prolong the time to ejaculation and results have been extremely positive. The inventor himself thinks this will become the next big thing. There are only two treatments available in the UK for the treatment of PE, Priligy and Emla. One is expensive and the other one can produce a numbing sensation so can defeat the purpose.

Tempe is said to help men last three times longer than they normally would and is inexpensive compared with the existing effective treatments. The treatment contains low dose anaesthetics and starts working within 5 minutes.

The pharmaceutical company responsible for the drug, Plethora Solutions, is feeling positive about gaining European approval and estimate that the treatment will be available in 2013.

Ampio Pharmaceuticals has completed an extension study for its premature ejaculation drug, Zertane, which began on the back of their successful phase III trials. The aim of the study was to evaluate the safety and efficacy of Zertane in the treating of premature ejaculation.

101 participants were given a higher dose of the drug and they received a follow-up every 3 weeks on four occasions. Only 6 participants experienced adverse effects and this came in the form of either anxiety or erectile dysfunction.

There were no serious adverse events reported during the Zertane phase III trial or this extension study and the number of such events reported were few. Only one event was treatment related. It was revealed that accompanied by a longer follow-up, even the higher dose of this drug is safe.

Zertane is likely to get the approval it is seeking considering that its active ingredient, Tramadol hydrochloride, is already on the market and the results of this extension study have been altogether positive. It is believed that approximately 23% of men suffer from premature ejaculation so it is surprising that there is still only one treatment on the market, Priligy. We will keep an eye out for this treatment but if the manufacturer gets the pricing right, this has the potential to be a blockbuster drug.

The latest in premature ejaculation (PE) news reveals positive results for Zertane, a new premature ejaculation treatment that has just been through phase III clinical trials. It was tested at both a low dose and at a high dose. Ampio Pharmaceuticals, the manufacturers, are now eager to get this drug on the market in Europe and Asia.

The success of the drug is measured on the length of time the penis can penetrate the vagina before ejaculating. This is described as intravaginal ejaculatory latency time (IELT). The lower dose lengthened the mean IELT by 4.07 times the length of time observed at the trials outset. The higher dose increased the mean IELT by 4.26 fold.

Men in the group whose median IELT was less than 60 seconds at the baseline experienced even greater benefits from the drug where the IELT increase was at 5.2 fold on the lower dose and 6.0 fold on the higher dose.

Priligy is the only oral drug that has been approved for the treatment of premature ejaculation. Considering Zertane appears to be even more effective than Priligy, the drug stands to do very well in this emerging treatment area.

It is estimated that 23% of men suffer from premature ejaculation (defined as reaching orgasm within 2 minutes of penetration) so this is a potentially large market. As Zertane contains Tramadol Hydrochloride as the active ingredient, we believe that the approval should be fast tracked in Europe as Tramadol has been used for a number of years as a pain killer. This is definitely one to watch.

A new treatment for premature ejaculation is being tested and involves the heating of the dorsal penile nerve. This heating weakens the nerve that sends messages of pleasure to the brain during sexual activity.

The therapy sounds a little invasive including a local anaesthetic and a hollow needle which is inserted into the pelvis through the skin. Here a low level current is sent through an electrode attached to the needle, heating the nerve until it is almost destroyed. This desensitization intends to make the man last longer during sexual activity while messages are blocked from travelling to the brain.

It sounds daunting and risky but this nerve actually repairs itself over time meaning men will have to have repeat treatments over time but also that the effects will not be permanent and there is no way of damaging the nerve long term.

Previous methods of desensitising the dorsal penile nerve have left men with no sexual sensation and a large number could not thereafter achieve an erection. Previous attempts have involved the severing of the nerve. This heating of the nerve though is a far less severe a procedure as rather than removing the nerve, they are reducing sensation by heating it.

This procedure does sound a little excessive when there are other non-invasive solutions but for men who have been unable to find success with these treatments, this could be a piece of welcome news.

Promising results have been presented from clinical trials into a new spray to treat premature ejaculation. The researchers testing the new treatment say that is could help men suffering from P.E last 6 times longer.

That said, men who used the spray lasted an average of 3 minutes, compared with just over 30 seconds when they did not use it. Premature ejaculation is defined as ejaculation that occurs within one minute of vaginal penetration and is thought to affect up to 30% of men.

The spray, currently known as PDS502, is sprayed on the penis before sex. It is being developed by Shionagi Pharma Inc, who pay the leader of the clinical trial as a consultant. Ira Sharlip, clinical professor of urology at the University of California, has said that he is particularly excited to be involved in rigorous clinical trials for a P.E project.

Though Priligy, Jansenn-Cilag’s new pill for premature ejaculation, has been rigorously trialed, generally products sold as premature ejaculation cures promise amazing things but have little scientific data to back them up.

There have been two pivotal trials into PSD502, involving 530 men with premature ejaculation in total. They were either given a placebo spray or the real medication and were asked to administer 3 sprays to the penis, which was then wiped off before penetration. The spray contains two topical painkillers, lidocaine and prilocaine, and is described as ‘oily but not unpleasantly so’.

The men were asked to calculate their intercourse times (using a stopwatch – erotic!) and as well as reporting longer-lasting erection times, they also said that they experienced better ejaculatory control.

There were however side effects reported by their partners, with the most frequent being burning in the vaginal area.

The company are planning on applying for FDA approval in the near future.

The first pharmaceutical based premature ejaculation spray to be sold over the counter will be available for purchase in the States this year. Promescent will be presented at the American Urological Association’s Annual Meeting in Washington this month by G and H Brands LLC: the product that has all of the top urologists and sex therapists hailing this new spray as a breakthrough treatment for premature ejaculation.

Promescent is a topical spray that controls the hypersensitivity of the penis that causes many of the cases of premature ejaculation with the application of Lidocaine, its key ingredient.

No prescription will be required for this treatment and as the sensitivity of the penis varies greatly from man to man, the amount of treatment applied is optional making the product all the more attractive to men who want to control this type of sexual dysfunction. At first the premature ejaculation treatment will only be available in the US but considering the excitement surrounding its launch so far, it looks likely that the product will be available internationally in time.

Anyone wishing to use this product should be aware that it could cause a desensitisation in the female partner to a condom should really be used.

One of the largest ever public surveys into premature ejaculation has shown that men are deeply reluctant to seek help for the condition, though it causes them great suffering and can put unbearable strain on their relationships.

Janssen-Cilag, who have developed the first ever pill for the condition, commissioned the survey, which saw over 4,500 men from 9 European countries asked about how premature ejaculation impacted on their lives and what they thought attitudes were to the condition.

The survey was also supported by various sexual health charities and support groups for men suffering from erectile dysfunction, including the European Sexual Health Alliance and the European Men’s Health Forum.

1 in 3 men said that the condition made them feel angry, ashamed or depressed while half of the men revealed that they felt to blame for it, which in turn made them feel guilty. Half also said that they have never discussed the condition with anyone, even their partners, with some suffering in silence for over 25 years.

Dr. Ian Banks, President of the European Men’s Health Forum, said that the survey clearly revealed that the condition was still a taboo subject, with the stigma attached to it preventing many men from talking and talking action.

Only 1 in 10 men said they had spoken to a healthcare professional about the problem, with half of those who had not saying they felt too embarrassed and 28% saying they did not consider it to be a medical problem.

With premature ejaculation the most common sexual problem reported by men, the study is a distressing indication how many men endure the condition alone and unsupported. It is to be devoutly hoped that the development of a medication to treat the disorder will lead to it being discussed openly and unashamedly, as happened with Viagra and erectile dysfunction.